Abbott Laboratories (ABT) DIvidends Date & History

Key Takeaways

• Abbott Laboratories offers a forward dividend yield of approximately 2.45%, paid quarterly at $0.63 per share.
• The company boasts a 54-year streak of consecutive dividend increases, earning Dividend King status.
• Payout ratio stands at around 64%, indicating solid earnings coverage for the dividend.
• Free cash flow comfortably covers dividends, with a 2024 FCF payout ratio of about 60%.
• ABT's yield is competitive within the healthcare sector, appealing to income and growth investors.
• Next ex-dividend date is April 15, 2026, with payment on May 15, 2026.

Dividend Overview

Abbott Laboratories (ABT), a diversified healthcare giant specializing in diagnostics, medical devices, nutrition, and established pharmaceuticals, maintains a robust dividend policy. The company pays a quarterly dividend of $0.63 per share, annualizing to $2.52 and yielding about 2.45% based on recent trading levels. This positions ABT as a classic dividend growth stock, balancing reliable income with consistent raises over decades. With 399 consecutive quarterly payments since 1924 and 54 years of increases, Abbott exemplifies shareholder commitment. The yield exceeds the S&P 500 average while remaining sustainable, attracting investors seeking stability in the healthcare sector.

Dividend History and Growth

Abbott Laboratories has a storied dividend history, declaring dividends without interruption since 1924 and raising payouts for 54 consecutive years, securing its place among S&P 500 Dividend Aristocrats and Kings. Recent growth reflects this commitment: the quarterly dividend rose 6.8% to $0.63 in early 2026 from $0.59. Over the past year, dividends grew 7.14%; three years at 7.72%; and five years at 9.42%. This compounding trend underscores Abbott's long-term strategy of sharing success with shareholders amid expanding operations in high-margin areas like diabetes care and diagnostics. No cuts have occurred in over a century, highlighting payment consistency.

Dividend Sustainability and Payout Ratio

Abbott's dividend sustainability is strong, supported by a payout ratio of approximately 64% of earnings, leaving ample room for reinvestment and future hikes. Free cash flow (FCF) coverage is equally reassuring: in 2024, FCF reached $6.35 billion against $3.84 billion in dividends, yielding a 60% FCF payout ratio. Operating cash flow covered dividends 2.23 times. Debt levels remain manageable post-acquisitions, with leverage expected to moderate. Earnings per share growth and diversified revenue streams—less cyclical than many peers—bolster confidence in ongoing coverage, even as capex supports innovation in devices and diagnostics.

Dividend Compared to Industry Peers

Abbott Laboratories' 2.45% yield sits comfortably among healthcare peers. Medtronic (MDT) offers a higher 3.2% yield but with a 79% payout ratio, signaling less growth flexibility. Johnson & Johnson (JNJ) yields 2.18% at a conservative 47% payout. Becton Dickinson (BDX) matches closely at 2.7% with 68% payout, while Stryker (SYK) trails at 1.0% amid rapid growth focus. ABT's profile—solid yield with superior growth history—stands out versus the sector's 1.6-1.9% average.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. It excels at identifying dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to uncover hidden gems like reliable dividend payers in healthcare.

Is This Stock Attractive for Dividend Investors?

Abbott Laboratories appeals to dividend growth investors prioritizing longevity and compounding returns, given its 54-year increase streak and 9%+ five-year growth rate. Income seekers may appreciate the 2.45% yield, competitive in healthcare, paired with quarterly payouts and strong FCF coverage reducing cut risks. Long-term, conservative investors value ABT's defensive qualities—recurring revenue from essentials like glucose monitoring and nutrition—offering resilience in downturns. However, the 64% payout ratio suggests moderation versus ultra-conservative plays, and growth may lag high-yield peers like MDT amid R&D demands. Balanced portfolios benefit from ABT's stability without excessive volatility, though sector exposures to regulation and competition warrant monitoring. Overall, it suits patient investors blending yield, growth, and quality.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations